Effectiveness of certolizumab pegol in chronic anterior uveitis associated to Crohn's disease and ankylosing spondylitis;Efectividad del certolizumab pegol en el tratamiento de la uveítis anterior crónica asociada a enfermedad de Crohn y espondilitis anquilosante

Reumatologia Clinica

Volumn 11, Issue 3, 2015, Pages 189-190

  Maiz Alonso, Olga ^a   Blanco Esteban, Ana Carmen ^a   Egües Dubuc, Cesar Antonio ^a   Martinez Zabalegui, David ^a  

^a HOSPITAL DONOSTIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CERTOLIZUMAB PEGOL; IMMUNOSUPPRESSIVE AGENT;

ANKYLOSING SPONDYLITIS; CHRONIC ANTERIOR UVEITIS; CHRONIC DISEASE; CLINICAL EFFECTIVENESS; CROHN DISEASE; DISEASE ASSOCIATION; DRUG EFFICACY; IRIDOCYCLITIS; LETTER; ADULT; CASE REPORT; COMPLICATION; HUMAN; MALE; UVEITIS, ANTERIOR;

ADULT; CERTOLIZUMAB PEGOL; CHRONIC DISEASE; CROHN DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; SPONDYLITIS, ANKYLOSING; UVEITIS, ANTERIOR;

EID: 84928161591     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2014.10.006     Document Type: Letter

References (11)

1. Llorenç V., Mesquida M., Sainz de la Maza M., Blanco R., Calvo V., Maíz O., et al. Certolizumab Pegol, a New Anti-TNF-α in the Armamentarium against Ocular Inflammation. Ocul Immunol Inflamm. 2014, 1-6. Oct 17.
2. Lyons J.L., Rosenbaum J.T. Uveitis associated with inflammatory bowel disease compared with uveitis associated with spondyloarthropathy. Arch Ophthalmol 1997, 115:61-64.
3. Muñoz-Fernández S., Hidalgo V., Fernández-Melón J., Schlincker A., Bonilla G., Ruiz-Sancho D., et al. Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol 2003, 30:1277-1279.
4. Benítez-Del-Castillo J.M., García-Sánchez J., Iradier T., Bañares A. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye (Lond) 2000, 14:340-343.
5. Muñoz-Fernández S., García-Aparicio A.M., Hidalgo M.V., Platero M., Schlincker A., Bascones M.L., et al. Methotrexate: An option for preventing the recurrence of acute anterior uveitis. Eye (Lond) 2009, 23:1130-1133.
6. Braun J., Baraliakos X., Listing J., Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005, 52:2447-2451. Review.
7. Rudwaleit M., Rødevand E., Holck P., Vanhoof J., Kron M., Kary S., et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: Results of a prospective open-label study. Ann Rheum Dis 2009, 68:696-701.
8. Gueudry J., LeHoang P., Bodaghi B. Anti-tumor necrosis factor-α agents in noninfectious uveitis. Dev Ophthalmol 2012, 51:63-78.
9. Cordero-Coma M., Salom D., Díaz-Llopis M., López-Prats M.J., Calleja S. Golimumab for uveitis. Ophthalmology 2011, 118:1892.e3-4.
10. Chapman A.P. Pegylated antibodies and antibody fragments for improved therapy: A review. Adv Drug Deliv Rev 2002, 54:531-545.
11. Palframan R., Airey M., Moore A., Vugler A., Nesbitt A. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collageninduced arthritis. J Immunol Methods 2009, 348:36-41.